Unlocking Inflammation Resolution
Resolve Reset Restore
Thinking Differently
In a game changing approach, Penta Therapeutics propose an innovative therapeutic strategy targeting inflammation resolution.
We posit that inherent or acquired defects in resolution pathways underpin at least some chronic inflammatory diseases.
By therapeutically re-invigorating endogenous inflammation resolution, we aim to RESOLVE inflammation, RESET normal immune function and RESTORE homeostasis.
Chronic inflammatory diseases represent the leading cause of mortality worldwide
Despite a high prevalence, chronic inflammatory diseases have no cure, treatments often have side effects, lose their potency and fail to tackle the underlying cause of disease. Current treatments focus on pro-inflammatory pathways to reduce the five pillars of inflammation - heat, pain, redness, swelling, and loss of function. In contrast, the process by which inflammation is normally brought to a successful resolution, are less well studied.
Harnessing the power of inflammation resolution
A new strategy is required to drive chronic inflammatory diseases into lasting remission. Our aim is to pursue the concept of inflammation resolution as a common denominator across a range of disabling and life-threatening chronic inflammatory diseases. At Penta Therapeutics we are taking an innovative approach to deliver next-generation therapeutics that will resolve inflammation, reset immune function and restore tissue healing and repair for millions of patients worldwide.
SEPSIS
AUTOIMMUNITY
IBD
RESPIRATORY
METABOLIC/
CARDIOVASCULAR
INFECTION
.png)
AGEING
Resolve. Reset. Restore.
1
Chronic Inflammatory Diseases are responsible for 3 in 5 deaths worldwide.
Autoimmune disorders damage healthy tissue, inflammation underpins cardiovascular, metabolic and neurodegenerative disease, and infection may acutely threaten life and limb through respiratory distress, sepsis and multiple organ failure.
2
Inflammation does not resolve passively
Once a threat of infection or injury has been neutralised, inflammation normally reaches a natural resolution. Pathogen clearance, macrophage efferocytosis of apoptotic cell debris, and the release anti-inflammatory cytokines transition inflammation into tissue healing and repair.
3
Inflammation Resolution may become dysregulated
In chronically inflamed tissues, Resolution Inhibitory Pathways (RIP’s) are upregulated in macrophages which subsequently fail to clear inflammatory sites, leading to self-perpetuating cycles of non-resolving chronic inflammation.
Translational Therapeutics Discovery
Proprietary immune cell assays and patient tissues generate authentic, non-resolving inflammation to drive our inflammation resolution concept.
State-of-the-art proteomics add critical data layers to support genetic and transcriptomic concepts at a molecular level, and multi-omic computational analysis reveals specific disease endotypes for patient stratification and biomarker identification.
In-house capabilities support modality-agnostic therapeutics discovery across a range of target classes and therapeutic approaches, including small molecules, protein degraders and antibody-mediated delivery.
Clinical disease expertise and human experimental models of inflammation, address the translational gap adding value through early human proof of concept studies.
Theraputic Discovery
Precision Medicine
Clinical Translation
Novel Disease Biology
.png)
Chronic inflammation encompasses a variety of disease endotypes
In a patient-centric approach, we are unravelling the biological diversity within chronic inflammatory diseases, mapping specific immune cell aberrations and disease endotypes within patient populations.
Multi-omic analysis of non-resolving macrophages revealed molecular targets that drive Resolution Inhibitory Pathways (RIP’s). Therapeutic intervention to downregulate RIP-target proteins presents a game-changing opportunity to re-invigorate immune resolution for millions of chronic inflammatory disease patents worldwide.
